Tier 1 — highest
Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial
Phytomedicine
2016
23(14):1735-1742
Bibliography
- PubMed
- PMID 27912875
- PubMed Central
- PMC5646235
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Study snapshot
| Design | Two-phase open-label run-in followed by randomized double-blind placebo-substitution trial |
|---|---|
| Model | Adults with moderate-to-severe generalized anxiety disorder who responded to open-label chamomile |
| Sample | 179 enrolled; 93 responders randomized |
| Intervention | Chamomile extract 1500 mg/day continued versus placebo after 12-week open-label response |
| Duration | 12-week open-label phase plus 26-week randomized continuation phase |
| Endpoints | Time to GAD relapse; Relapse proportion; GAD symptom severity; Adverse events; Vital signs |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Apigenin for Anxiety and Relaxation: What Does the Evidence Show?Does apigenin help anxiety? A 2026 evidence review of GABA mechanisms, chamomile trials, preclinical systematic-review data, dose, timing, medications and relaxation stacks.Read analysis
- Apigenin in Chamomile: How Much Is There and Does Chamomile Help Sleep?How much apigenin is in chamomile? A practical guide to tea, flowers, human absorption, sleep and anxiety evidence, cup-to-capsule comparisons and timing.Read analysis
- Apigenin for Sleep: Does It Actually Work?Does apigenin help sleep? A practical 2026 guide to human evidence, 50 mg protocols, timing, Huberman’s sleep stack, melatonin comparisons and safety.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
